# All Round Doctors

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/all-round-doctors

- Industry: Healthcare
- Headquarters: Seoul, South Korea
- Website: www.ards.co.kr/
- Total disclosed funding: $5.2M
- Latest round: Series A (Aug 6, 2024)
- Investors on record: 5

## About

Based in South Korea, All Round Doctors specializes in digital therapeutics, offering innovative software solutions that enhance patient care, particularly for those undergoing cancer therapies.All Round Doctors, founded in 2021 in Seoul, South Korea, focuses on providing digital therapeutic solutions to improve cancer treatment management. The company has raised KRW 7 billion in Series A funding, led by AON Investment, with participation from multiple investors. This funding will support clinical trials and market expansion efforts, particularly into Japan.All Round Doctors specializes in digital therapeutics, providing software solutions to personalize treatment for cancer patients. Their key products, CANMORE PRO and CANMORE, facilitate real-time reporting of side effects and assist patients in managing chemotherapy-related issues, improving treatment adherence and quality of life. The company collaborates with major medical institutions in South Korea and aims to expand services for patients with various cancer types.The revenue model of All Round Doctors is based on partnerships and direct service provision to healthcare institutions. Their products, CANMORE PRO and CANMORE, are integrated into hospital systems, with transactions structured around service agreements involving subscription or usage-based fees. Revenue growth is anticipated through collaborations with stakeholders in the healthcare sector, including pharmaceutical firms and research institutions.In August 2024, All Round Doctors secured KRW 7 billion in Series A funding, which will be used to enhance the medical stability and technological development of CANMORE. The company plans to conduct IRB clinical trials with the Ministry of Food and Drug Safety and aims to enter the Japanese market, facilitating broader access to their digital therapeutic solutions.

## Funding rounds

- Series A, Aug 6, 2024, $5.2M — KB Investment, UTC Investment, FuturePlay, AON Investment, Korean Investment Partners

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series A
- FuturePlay (https://capitalatlas.ai/funds/futureplay) — Series A
- AON Investment (https://capitalatlas.ai/funds/aon-investment) — Series A
- Korean Investment Partners — Series A